Showing results (31-40 of 131) with videos related to

Sort By:
Pageof 14
International Journal of Cancer|September 19, 2017
The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitorsMark C de Gooijer, Ping Zhang, Ruud Weijer, et al.
Cancer Chemotherapy and Pharmacology|February 28, 2002
Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gutHeleen A Bardelmeijer, Mariët Ouwehand, Mirte M Malingré, et al.
Cancer Research|April 5, 2005
The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patientsPauline Breedveld, Dick Pluim, Greta Cipriani, et al.
Investigational New Drugs|October 22, 2010
Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRPNienke A de Vries, Tessa Buckle, Jin Zhao, et al.
FEBS Open Bio|April 12, 2017
The G2 checkpoint-a node-based molecular switchMark C de Gooijer, Arnout van den Top, Irena Bockaj, et al.
International Journal of Cancer|April 15, 2015
ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-InhibitorsPing Zhang, Mark C de Gooijer, Levi C M Buil, et al.
Iscience|June 9, 2025
A pharmacokinetic study and critical reappraisal of curcumin formulations enhancing bioavailabilityMaurice A G M Kroon, Hanneke W M van Laarhoven, Eleonora L Swart, et al.
Investigational New Drugs|January 15, 2013
Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPASerena Marchetti, Dick Pluim, Monique van Eijndhoven, et al.
Molecular Pharmaceutics|September 26, 2018
ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461Mark C de Gooijer, Levi C M Buil, Ceren H Çitirikkaya, et al.
Plos One|October 3, 2012
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumorsSerge A L Zander, Wendy Sol, Lee Greenberger, et al.
Pageof 14